Disease progression after R-CHOP treatment associated with the loss of CD20 antigen expression

Marcelo Bellesso
Flavia Dias Xavier
Renata Oliveira Costa
Juliana Pereira
Sheila Aparecida Coelho Siqueira
Dalton Alencar Fischer Chamone

Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Instituto Octavio Frias, São Paulo, SP, Brazil

A case of a follicular lymphoma transformed into a CD20+ is described which progressed with the loss of CD20 expression after 8 cycles of R-CHOP. This phenomenon is not a rare event and has shown poor prognosis. Our purposes are to describe this event and suggest biopsy in relapsed or progressive disease.

Keywords: Lymphoma, Large B-cell, diffuse; Disease progression; Immunotherapy

Introduction

The use of rituximab – a chimeric monoclonal antibody against CD20 protein - has become a molecular target treatment for CD20+ B cell non-Hodgkin lymphoma (NHL). Rituximab associated with chemotherapy has been indicated for low and high grade B cell NHL and for the maintenance of relapsed follicular lymphoma. The R-CHOP protocol (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) is currently the gold standard treatment for diffuse large B cell lymphoma (DLBCL). Although this protocol attains the best rates of complete response (76%) and 4-year overall survival (55 to 94%), there is a considerable number of patients that are refractory to treatment or present early relapse. The relapse and overall survival rates depend on risk factors. Progression-free survival at 4 years for patients without risk factors, with 1 or 2 risk factors and with 3 or more risk factors is 6%, 20% and 47%, respectively.

Studies demonstrate that individual characteristics can influence the response of rituximab against CD20+ cells, such as the Fc gammaRIIIa-158V/F polymorphism, expression of the CD20 antigen and CD20-positive tumor burden.

Currently, it is extremely difficult to define resistance to rituximab, however some mechanisms have been described with unclear clinical meanings such as: the loss of CD20 antigen expression, mechanisms of antigen-antibody binding interactions and the expression of inhibitors including CD55 and CD59 antigens, among others.

Recently, loss of CD20 expression was demonstrated in refractory and/or relapsed cases treated with rituximab-based chemotherapy. This fact should be considered carefully, since almost all second line protocols are based on the association of rituximab with chemotherapy (R-ICE and R-DHAP). Our purpose is to describe the case of a follicular lymphoma transformed into CD20+, which progressed with the loss of CD20 antigen expression after an R-CHOP regimen.

Case Report

In September of 2008, a 58-year-old woman presented with a follicular lymphoma transformed into CD20+, stage IV XEB (bone marrow infiltration, retroperitoneal bulky disease, pleural infiltration), with three risk factors (clinical stage IV, elevated lactate dehydrogenase and more than one extra nodal site). The biopsy of an abdominal lymph node identified DLBCL while the bone marrow biopsy was characterized by follicular lymphoma infiltration.

She was treated with pre-phase therapy (cyclophosphamide 600 mg/m² day 1, vincristine 1.4 mg/m² day 1 and prednisone 100 mg days 1-5) followed by 8 cycles of R-CHOP given every 21 days. Ten days after the last cycle of chemotherapy, subcutaneous nodules appeared in the abdomen with infiltration in the skin. Fine needle aspiration biopsy and skin biopsy were performed that identified infiltration of the skin by diffuse atypical monomorphic medium to large-sized lymphocytes. Immunohistochemistry demonstrated a
CD20-negative antigen, a CD79a-positive antigen, a high positive Ki-67 index and a focal CD3-positive antigen that was compatible with progressive disease characterized by the CD20-positive antigen expression; this phenomenon was confirmed by flow cytometry.

The patient started treatment in April 2009 with the IVAC protocol (ifosfamide, etoposide and cytarabine) and 2 cycles of high-dose methotrexate (3.5 g/m²), but she was refractory. She died in September 2009 five months after confirmation of progression.

Discussion

This case shows the loss of CD20-antigen expression during the evolution of a transformed lymphoma. This phenomenon raises some questions: what is the real incidence of this event? How do these new CD20-negative lymphomas behave? Are we searching for the diagnosis? What are the biological findings of this new entity? Currently, these questions cannot be answered.

There are few reports in the literature about the loss of CD20 antigen expression after treatment with rituximab. These studies are not homogeneous and do not have a prospective methodology. There are two main studies that try to estimate the incidence of this phenomenon, however according to the authors, because they did not carry out biopsies on all relapsed patients and those with progressive disease, the analysis of the frequency of CD20-antigen loss is extremely inaccurate. Kennedy et al. carried out biopsies on ten of 13 relapsed cases; CD20-antigen loss was found in six (46%). Hiraga et al. performed biopsies in nineteen of thirty-six relapsed cases; five cases had lost the CD20-antigen expression corresponding to 14% of all relapses and two had transformed follicular lymphoma. In most cases, performing a further biopsy in relapsed or progressive disease cases was related to an aggressive or unusual presentation as in our report, where the relapse was characterized by subcutaneous nodules and skin infiltration that culminated in the patient's death just five months after relapse and one year after diagnosis. Hiraga et al. also had 100% of mortality in five cases with maximum survival of eleven months after the confirmation of CD20-antigen loss.

There are some explanations for the pathogenesis of CD20-antigen loss in CD79a-positive lymphomatoid B cells.
First, it may be explained by a virtual blockade of all CD20-antigen sites binding to rituximab. Second, the existence of CD20-negative cells could have been positively selected by rituximab. On the other hand, CD20-positive B cells might have mutated leading to loss of expression resulting in the absence of transcription or the internalization of the CD20 antigen.

A possible explanation of CD20-antigen loss was demonstrated by Higara et al. using B cell lineages derived from CD20-negative relapsed patients. The authors showed that the \textit{in vitro} treatment of these cells using 5-aza-2’deoxicitidin stimulated gene expression resulting in higher levels of CD20 Mrna. This case illustrates the importance of carrying out further biopsies during the evaluation of relapsed or progressive B cell NHL who are candidates for rituximab rescue therapy. Moreover, the loss of CD20-antigen expression seems to be related to a poor prognosis. Thus, more studies are necessary to elucidate the real incidence and importance of this phenomenon in the follow-up of B cell NHL treated with rituximab.

\textbf{References}

1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-2.

2. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(3):1857-61.

3. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gamma gene. Blood. 2002;99(3):754-8.

4. Van Meertens T, Van Rijn RS, Hol S, Hagenbeek A, Ebeing SB. Complement-induced cell death by rituximab depends on D20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res. 2006;12 (13):4027-35.

5. Daydé D, Ternant D, Ohresser M, Lerondel S, Pesnel S, Watier H, et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood. 2009;113(16):3765-72.

6. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22(47):7359-68.

7. Ferreri AJ, Dognini GP, Verona C, Patriarca C, Doglioni C, Ponzi M. Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma. Haematologica. 2007;92(1):e1-2.

8. Clarke LE, Bayerl MG, Ehmann WC, Helm KF. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy. J Cutan Pathol. 2003;30(7):459-62.

9. Pereira J, Bellesso M, Pracchia LF, Neto AE, Beiter B, de Almeida Macedo MC, et al. Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil. Leuk Res.2006;30(6):681-5.

10. Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol. 2002;119 (2):412-6.

11. Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009;113(20):4885-93.

12. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 1999;5(3):611-5.